Wednesday, July 8, 2026

Intelligence · Clinical Development

Pipeline search results

Programs matching “fluorouracil” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.

Matching programs 15
Total indexed 20,548
Sponsors 1,769

Quick answer

Showing 15 pipeline programs matching "fluorouracil" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.

Refine search

15 results for “fluorouracil” Back to intelligence hub

Search results

  1. 5-Fluorouracil

    Hoffmann-La Roche

    Breast Cancer

    phase 3 small molecule completed

    1 trial
  2. Docetaxel, cisplatin and fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Nasopharyngeal Carcinoma

    phase 3 small molecule active

    1 trial
  3. FLUOROURACIL for Rectal cancer

    Disc Medicine

    Rectal cancer

    phase 3 small molecule active

    1 trial
  4. Irinotecan liposome、5-Fluorouracil、Leucovorin

    Jian Li

    Second-line Treatment for Locally Advanced or Metastatic Pancreatic Cancer After Treatment Failure With Gemcitabine-based Therapy

    phase 3 small molecule completed

    1 trial
  5. 5-Fluorouracil

    Hospital Authority, Hong Kong

    Cancer (Advanced Stage)

    phase 2 small molecule active

    1 trial
  6. 5-Fluorouracil (5-FU)

    HALOZYME THERAPEUTICS, INC.

    Gastric Adenocarcinoma or Gastroesophageal Junction Adenocarcinoma or Esophageal Carcinoma

    phase 2 small molecule completed

    1 trial
  7. CMUH-HO-NPC001

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Head and Neck Carcinoma

    phase 2 small molecule completed

    1 trial
  8. Cyclophosphamide+Pemetrexed+5-Fluorouracil

    Xiyuan Hospital of China Academy of Chinese Medical Sciences

    Locally Advanced Thyroid Gland Carcinoma

    phase 2 small molecule active

    1 trial
  9. FEMH-95011

    Hospital Authority, Hong Kong

    Stomach Neoplasms

    phase 2 small molecule active

    1 trial
  10. Fluorouracil

    United Therapeutics Europe Ltd

    Metastatic Biliary Tract Carcinoma

    phase 2 small molecule active

    1 trial
  11. Fluorouracil

    United Therapeutics Europe Ltd

    Clinical Stage II Esophageal Adenocarcinoma AJCC v8

    phase 2 small molecule active

    1 trial
  12. Fluorouracil

    Arcus Biosciences

    Borderline Resectable Pancreatic Adenocarcinoma

    phase 2 small molecule active

    1 trial
  13. Fluorouracile AHCL /ml for colorectal cancer

    Fondazione Telethon ETS

    colorectal cancer

    phase 2 small molecule active

    1 trial
  14. GM-CT-01 plus 5-Fluorouracil

    GALECTIN THERAPEUTICS INC

    Colorectal Cancer

    phase 2 small molecule terminated

    1 trial
  15. Phase 1b/2 trial of 5-fluorouracil for metastatic colorectal cancer

    Fondazione Telethon ETS

    metastatic colorectal cancer

    phase 2 other active

    1 trial

Frequently asked questions

What is the Clinical Development Intelligence Platform?

It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.

How does this compare to Evaluate Pharma or Citeline?

Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.

Where does pipeline data come from?

Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.

Can I follow a company or program for updates?

Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.